▶ 調査レポート

精神分裂病治療薬の世界市場:薬物クラス別、投与経路別

• 英文タイトル:Schizophrenia Drugs Market (Drug Class: First Generation Drugs, Second Generation Drugs, and Third Generation Drugs; Route of Administration: Oral and Injectable) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
• レポートコード:TPM-NV210
• 出版社/出版日:Transparency Market Research / 2019年10月
• レポート形態:英文、PDF、148ページ
• 納品方法:Eメール
• 産業分類:製薬
• 販売価格(消費税別)
  Single User¥625,860 (USD5,795)▷ お問い合わせ
  Multi User¥949,860 (USD8,795)▷ お問い合わせ
  Global Site License¥1,273,860 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、精神分裂病治療薬の世界市場について調べ、精神分裂病治療薬の世界市場規模、市場動向、市場シェア、市場環境、市場予測、薬物クラス別(第一世代薬物、第二世代薬物、および第三世代薬物)分析、投与経路別(経口および注射)分析、関連企業情報などをまとめました。
・精神分裂病治療薬の市場概要
・精神分裂病治療薬の市場動向
・精神分裂病治療薬の世界市場規模・予測
・精神分裂病治療薬市場:薬物クラス別(第一世代薬物、第二世代薬物、および第三世代薬物)
・精神分裂病治療薬市場:投与経路別(経口および注射)
・地域別分析(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争環境・関連企業分析

Several doctors and healthcare providers are adopting the methods of polypharmacology to develop new drugs for mental disorders. These methods are providing better outcomes in patients as compared to single-target drugs in the schizophrenia drugs market.

Likewise, multi-target drugs are emerging as an effective alternative to treat polygenic diseases, including schizophrenia. As such, the second-generation drugs market is estimated to reach ~US$ 11.1 billion by the year 2027; the highest amongst all drug classes in the schizophrenia drugs landscape. These second-generation drugs, i.e. atypical antipsychotics, target a number of aminergic G-protein coupled receptors (GPCRs) to treat complex pathomechanisms of schizophrenia.

Pharmaceutical companies are increasing research & development related to the schizophrenia drugs market to develop drugs that are beyond the dopaminergic hypothesis of schizophrenia and beyond monoamine G protein coupled receptors (GPCRs). They are increasing their production capacities of dopamine antagonists and drugs meant to effectively control the symptoms of schizophrenia and improve patient quality of life. Manufacturers in the schizophrenia drugs market are also turning towards other second-generation antipsychotics, such as serotonin and histamine, to prevent amphetamine-induced behavioral changes in patients.

レポート目次

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Schizophrenia Drugs Market

4. Market Overview

4.1. Introduction

4.1.1. Schizophrenia Drugs Introduction

4.1.2. Market Evolution/Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Schizophrenia Drugs Market Analysis and Forecast, 2017–2027

4.4.1. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast

5. Key Insights

5.1. Pipeline Analysis: Schizophrenia Drugs

5.2. Value Chain Analysis

5.3. Global Schizophrenia Drugs Sales Analysis, 2017–2027

6. Global Schizophrenia Drugs Market Analysis and Forecast, by Drug Class

6.1. Introduction & Definitions

6.2. Key Findings / Developments

6.3. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

6.3.1. First Generation Drugs

6.3.2. Second Generation Drugs

6.3.3. Third Generation Drugs

6.4. Global Schizophrenia Drugs Market Attractiveness, by Drug Class

7. Global Schizophrenia Drugs Market Analysis and Forecast, by Route of Administration

7.1. Introduction & Definitions

7.2. Key Findings / Developments

7.3. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

7.3.1. Injectable

7.3.2. Oral

7.4. Global Schizophrenia Drugs Market Attractiveness, by Route of Administration

8. Global Schizophrenia Drugs Market Analysis and Forecast, by Region

8.1. Key Findings

8.2. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Region

8.2.1. North America

8.2.2. Europe

8.2.3. Asia Pacific

8.2.4. Latin America

8.2.5. Middle East & Africa

8.3. Global Schizophrenia Drugs Market Attractiveness, by Region

9. North America Schizophrenia Drugs Market Analysis and Forecast

9.1. Introduction

9.1.1. Key Findings

9.2. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

9.2.1. First Generation Drugs

9.2.2. Second Generation Drugs

9.2.3. Third Generation Drugs

9.3. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

9.3.1. Injectable

9.3.2. Oral

9.4. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country, 2017–2027

9.4.1. U.S.

9.4.2. Canada

9.5. North America Schizophrenia Drugs Market Attractiveness Analysis

9.5.1. By Drug Class

9.5.2. By Route of Administration

9.5.3. By Country

10. Europe Schizophrenia Drugs Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Findings

10.2. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

10.2.1. First Generation Drugs

10.2.2. Second Generation Drugs

10.2.3. Third Generation Drugs

10.3. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

10.3.1. Injectable

10.3.2. Oral

10.4. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

10.4.1. Germany

10.4.2. U.K.

10.4.3. France

10.4.4. Italy

10.4.5. Spain

10.4.6. Rest of Europe

10.5. Europe Schizophrenia Drugs Market Attractiveness Analysis

10.5.1. By Drug Class

10.5.2. By Route of Administration

10.5.3. By Country/Sub-region

11. Asia Pacific Schizophrenia Drugs Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

11.2.1. First Generation Drugs

11.2.2. Second Generation Drugs

11.2.3. Third Generation Drugs

11.3. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

11.3.1. Injectable

11.3.2. Oral

11.4. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

11.4.1. China

11.4.2. India

11.4.3. Japan

11.4.4. Australia & New Zealand

11.4.5. Rest of Asia Pacific

11.5. Asia Pacific Schizophrenia Drugs Market Attractiveness Analysis

11.5.1. By Drug Class

11.5.2. By Route of Administration

11.5.3. By Country/Sub-region

12. Latin America Schizophrenia Drugs Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

12.2.1. First Generation Drugs

12.2.2. Second Generation Drugs

12.2.3. Third Generation Drugs

12.3. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

12.3.1. Injectable

12.3.2. Oral

12.4. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Rest of Latin America

12.5. Latin America Schizophrenia Drugs Market Attractiveness Analysis

12.5.1. By Drug Class

12.5.2. By Route of Administration

12.5.3. By Country/Sub-region

13. Middle East & Africa Schizophrenia Drugs Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

13.2.1. First Generation Drugs

13.2.2. Second Generation Drugs

13.2.3. Third Generation Drugs

13.3. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

13.3.1. Injectable

13.3.2. Oral

13.4. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

13.4.1. GCC

13.4.2. South Africa

13.4.3. Rest of Middle East & Africa

13.5. Middle East & Africa Schizophrenia Drugs Market Attractiveness Analysis

13.5.1. By Drug Class

13.5.2. By Route of Administration

13.5.3. By Country/Sub-region

14. Competition Landscape

14.1. Global Schizophrenia Drugs Market Share Analysis, by Company (2018)

14.2. Company Profiles

14.2.1. Allergan

14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.1.2. Financial Overview

14.2.1.3. Product Portfolio

14.2.1.4. SWOT Analysis

14.2.1.5. Strategic Overview

14.2.2. Otsuka Holdings Co., Ltd

14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.2.2. Financial Overview

14.2.2.3. Product Portfolio

14.2.2.4. SWOT Analysis

14.2.2.5. Strategic Overview

14.2.3. Janssen Pharmaceutica (Johnson & Johnson)

14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.3.2. Financial Overview

14.2.3.3. Product Portfolio

14.2.3.4. SWOT Analysis

14.2.3.5. Strategic Overview

14.2.4. Pfizer Inc.

14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.4.2. Financial Overview

14.2.4.3. Product Portfolio

14.2.4.4. SWOT Analysis

14.2.4.5. Strategic Overview

14.2.5. Maynepharma

14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.5.2. Financial Overview

14.2.5.3. Product Portfolio

14.2.5.4. SWOT Analysis

14.2.5.5. Strategic Overview

14.2.6. Vanda Pharmaceuticals Inc.

14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.6.2. Financial Overview

14.2.6.3. Product Portfolio

14.2.6.4. SWOT Analysis

14.2.6.5. Strategic Overview

14.2.7. Sumitomo Dainippon Pharma

14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.7.2. Financial Overview

14.2.7.3. Product Portfolio

14.2.7.4. SWOT Analysis

14.2.7.5. Strategic Overview

14.2.8. Eli Lilly & Co.

14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.8.2. Financial Overview

14.2.8.3. Product Portfolio

14.2.8.4. SWOT Analysis

14.2.8.5. Strategic Overview

14.2.9. AstraZeneca Plc

14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.9.2. Financial Overview

14.2.9.3. Product Portfolio

14.2.9.4. SWOT Analysis

14.2.9.5. Strategic Overview




• 英文レポート名:Schizophrenia Drugs Market (Drug Class: First Generation Drugs, Second Generation Drugs, and Third Generation Drugs; Route of Administration: Oral and Injectable) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
• 日本語訳:精神分裂病治療薬の世界市場:薬物クラス別、投与経路別
• レポートコード:TPM-NV210お問い合わせ(見積依頼・ご注文・質問)